within Pharmacolibrary.Drugs.V_Various.V09A_CentralNervousSystem.V09AB03_IodineIoflupane123i;

model IodineIoflupane123i
  extends Pharmacolibrary.Drugs.ATC.V.V09AB03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>V09AB03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Iodine ioflupane (123I), also known as [123I]FP-CIT or DaTSCAN, is a radiopharmaceutical used in SPECT imaging to visualize dopamine transporters in the striatum. It is primarily used for the diagnosis of Parkinsonian syndromes and dementia with Lewy bodies. It is an approved agent used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following a single intravenous administration.</p><h4>References</h4><ol><li><p>Takahashi, M, et al., &amp; Kaneko, A (2017). [Evaluation of Early-phase Biodistribution in . <i>Nihon Hoshasen Gijutsu Gakkai zasshi</i> 73(9) 731–736. DOI:<a href=\"https://doi.org/10.6009/jjrt.2017_JSRT_73.9.731\">10.6009/jjrt.2017_JSRT_73.9.731</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28931769/\">https://pubmed.ncbi.nlm.nih.gov/28931769</a></p></li><li><p>Monti, DA, et al., &amp; Newberg, AB (2019). N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson&#x27;s Disease. <i>Clinical pharmacology and therapeutics</i> 106(4) 884–890. DOI:<a href=\"https://doi.org/10.1002/cpt.1548\">10.1002/cpt.1548</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31206613/\">https://pubmed.ncbi.nlm.nih.gov/31206613</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end IodineIoflupane123i;
